Expert Opinion on Drug Metabolism & Toxicology

Article	Citations
Probing the mechanism of reduced in vivo potency of insulin detemir	118
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	111
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	69
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	60
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury	58
Hormones, microbes, and PrEP drugs in the female genital tract	51
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	48
Comorbidities and the right dose: antipsychotics	32
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	32
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	30
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas	27
Guidance for interactions between antiseizure medications	26
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	25
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	24
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease	23
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	23
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	22
Correction	21
Bioactivity descriptors for in vivo toxicity prediction: now and the future	21
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	19
A comprehensive review of the efficacy and safety of ertugliflozin	19
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	18
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	17
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition	17
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	17

The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	17
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	17
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	16
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	16
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	16
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	16
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	16
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	14
Drug-drug interactions between psychotropic medications and oral contraceptives	14
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation	13
Risk factors and prediction for DILI in clinical practice	13
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	13
Population pharmacokinetic–pharmacodynamic analysis of givinostat	13
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature	12
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies	12
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data	12
Recent progress in machine learning approaches for predicting carcinogenicity in drug development	12
Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction	12
The impact of advanced age on anticoagulant therapy for acute venous thromboembolism	12
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review	11
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study	11
Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity	11
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants	11
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes	10
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction	10
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion	10
PBPK models of the female reproductive tract: current and future analysis	10
An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease	10
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects	10
Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjec	10
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study	9
Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug–drug interactions	9
Overcoming barriers to machine learning applications in toxicity prediction	9
Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far	9
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature	9
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling	9
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention	9
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies	9
The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications	9
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome	9
High-throughput PBTK models for in vitro to in vivo extrapolation	9
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers	8
Positioning the new drugs for migraine	8
Cardiomyocyte-specific CYP2J2 and its therapeutic implications	8
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease	8
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	8
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults	8
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	7
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?	7
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	7

Managing intoxications with nicotine-containing e-liquids	7
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	7
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	7
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	7
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	7
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	7
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	7
Drug interactions in people with HIV treated with antivirals for other viral illnesses	7
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	7
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	7
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	7
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics	6
The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics	6
Drug–drug interactions in HIV-infected patients receiving chemotherapy	6
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study	6
Pharmacokinetic studies in dialysis-dependent patients: limited data availability	6
DILI prediction in drug development: present and future	6
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers	6
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage	6
Strategies for the treatment of acute benzodiazepine toxicity in a clinical setting: the role of antidotes	5
Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens	5
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia	5
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment	5
A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database	5
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs	5
Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it	5
Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation	5
Drug–drug interactions involving antipsychotics and antihypertensives	5
Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review	5
Optimizing drug therapy during pregnancy: a spotlight on population pharmacokinetic modeling	5
Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy	5
How can we better address the pharmacokinetics of antipsychotics in children and adolescents?	5
Individualizing doses of antiepileptic drugs	5
In vitro neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity	5
Metabolic and toxicological considerations of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma	5
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?	5
Interindividual variability in statin pharmacokinetics and effects of drug transporters	5
The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: a systematic review and meta-analysis	5
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	5
A comparative study on the consistency of different decision support software systems from the perspective of potential drug–drug interactions in intensive care unit patients	5
The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions	5
A novel in vivo approach to monitoring Cyp3a induction and inhibition by bioluminescent urinalysis	5
Screening tools to evaluate the neurotoxic potential of botanicals: building a strategy to assess safety	5
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer	5
A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens	5
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol	5
Genetic variation in organic cation transporters and considerations in drug development	5
Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors	4
Cephalosporins with warfarin increase the risk of bleeding: myth or fact?	4
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	4
Ceftriaxone and methicillin-susceptible staphylococcus aureus: a perspective from pharmacokinetics/pharmacodynamics studies	4
Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke	4
The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?	4
A critical review of methotrexate clinical interactions: role of transporters	4
Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new?	4
Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis	4
CAR-T cell therapies for cancer: what novel technologies are being developed for toxicity data?	4
Absorption, distribution, metabolism and excretion of hyaluronic acid during pregnancy: a matter of molecular weight	4
Lessons learned from the influence of CYP2C9 genotype on warfarin dosing	4
Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond	4
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy	4
Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems	4
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity	4
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia	4
In silico prediction of drug-induced nephrotoxicity: current progress and pitfalls	4
Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients	4
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis	4
Cannabidiol: metabolism and clinical efficacy in epileptic patients	4
The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review	4
The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events	4
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia	4
Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated	4
Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older	4
Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections	4
Transporters and drug secretion into human breast milk	4
A repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in NOG mice by intravenous injection	3
Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation	3
Sex-gender differences in pharmacokinetics	3
Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update	3
Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil	3

What is the impact of metabolic dysfunction–associated steatotic liver disease on drug transport and metabolism?	3
Toward regulatory acceptance and improving the prediction confidence of in silico approaches: a case study of genotoxicity	3
JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations	3
Impact of pediatric continuous renal replacement therapy parameters on meropenem, piperacillin, and tazobactam pharmacokinetics: an in vitro model	3
Where developmental toxicity meets explainable artificial intelligence: state-of-the-art and perspectives	3
Sex-specific UGT expression and function: prevalence, potential mechanisms and significance	3
Improving on in-silico prediction of oral drug bioavailability	3
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration	3
Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects	3
The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions	3
What is the most effective and safest Non-steroidal anti-inflammatory drug for treating osteoarthritis in patients with comorbidities?	3
Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates	3
Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future	3
Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research	3
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach	3
Epigenetics is involved in the pleiotropic effects of statins	3
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review	3
The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review	3
Exposure to antibiotics during pregnancy alters offspring outcomes	3
Machine learning models in the prediction of drug metabolism: challenges and future perspectives	3
Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting	3
Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment	3
Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies	3
Modeling drug-induced liver injury: current status and future prospects	3
Inositols in the ovaries: activities and potential therapeutic applications	3
Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease	3
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro	3
Safety of medicines during breastfeeding – from case report to modeling: a contribution from the ConcePTION project	3